Elsevier Previews Second Generation Inteleos at SLA DPHT
Now Inteleos is the Most Intuitive and Comprehensive Tool to Track Brand and Generic Drug Development
Amsterdam, 7 April 2008 – Elsevier, a leading scientific and healthcare publisher previewed the second generation of Inteleos today at the SLA Division of Pharmaceutical & Health Technology Spring meeting in St. Petersburg, Florida. A redesigned interface and the addition of US approved and tentatively approved generic drugs – seamlessly linked to the branded drug – gives business intelligence professionals unparalleled breadth and depth of content.
Other enhancements to Inteleos include expanded drug records with detailed development timeline overviews, drug properties, ongoing trials, competitor profiles and related news. The new Competitor Profile highlights products with the same mechanism of action or drug class in a simple interactive grid giving users a snapshot of the competitive landscape. Graphical timelines track progress through development to product launch, including actual and company predicted dates, so users can visualize the path to approval.
“Once again, Inteleos is setting the pace in business intelligence,” observes Gerry Stoia, President, Pharmaceutical Intelligence. “No other product on the market today links generics seamlessly back to the branded drug. This, in combination with the most in-depth FDA and EMEA filing data, makes Inteleos an indispensable tool for portfolio management.”
Building on the already heralded design, the new interface focuses on improved usability. The reorganization of the search fields and addition of Boolean operators gives users the flexibility to conduct quick or complex searches. Combined with the expansive filter options, Inteleos makes it easier to pinpoint data most relevant to a user’s needs.
“Inteleos makes finding, analyzing and organizing data easy and the quality of our content gives users confidence in business strategy and portfolio management decision making,” says Director of Inteleos, Julie Gordon. “With Inteleos, users can save time by getting straight to the information they need, to give their company a competitive advantage.”
For more information and a demonstration visit the booth or attend the Vendor Update presentations on 8 April at SLA DPHT. If you are unable to attend the conference contact our helpdesk at Inteleos@elsevier.com for further information.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+31 20 305 1380